Pharmacolog i Uppsala AB (publ) announces that Erik Hedlund, acting CEO, returns to the role of chairman of the board and Lars Gusch, previously COO, has been appointed CEO of the company.
Pharmacolog’s board has today entered into a new agreement with current COO Lars Gusch, who will take over as CEO of the company with immediate effect. Lars Gusch was hired as COO at Pharmacolog in January 2022 and was previously development manager for the company in 2019-2020.
Erik Hedlund, chairman of the board, comments: “We are pleased that Lars has chosen to accept the position of managing Pharmacolog. Lars has had a significant role in implementing the SaaS offering and has extensive experience in both development and operational management in the company. Lars has also established good collaborations with Pharmacolog’s distributors and strategic partners and is thus prepared to broaden the distribution network to ensure high growth.”
For more information contact:
Erik Hedlund, chairman of the board
Phone: +46 70-382 08 41
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.
Further information regarding the company is available at https://pharmacolog.com/.
The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.